Skip to main content

Table 8 Use of immunomodulatory therapy—antibodies (reciprocal dilution)—by time interval

From: Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals

Categorical time

Number of individuals

Average time (days)

GMT (reciprocal dilution)

CONT (1–5 years)

4

1553 (1200–1800)

375.55

CONT (> 5–9 years)

26

2745 (1950–3240)

179.30

CONT (10 years)

11

3900 (3450–5520)

136.07

cs + bDMARD (1–5 years)

10

1233 (660–1830)

244.88

cs + bDMARD (> 5–9 years)

24

2686 (2070–3420)

126.81

cs + bDMARD (10 years)

13

5268 (3600–7500)

103.25